Magnetic processing of blood and plasma in the treatment of cancer

Updated: Mar 9

Professor Yuri Tkachenko. Dubai 2020.


Research and increase the effectiveness of currently used methods and means of treating cancer is one of the most important tasks in medicine. Recently, great attention has been paid to the physical methods of treating this disease, which, in combined use with chemoradiotherapy, can improve the results of treatment of cancer disease.

One of these methods is considered to be a system-wide magnetic vortex magnetic therapy. Abbreviated VMF.


These exercises are based on the principle of an ordered and cyclically changing effect on the entire or individual parts of the human body of a weak low-frequency VMF (vortex magnetic field). During the treatment, the magnetic induction vector rotates with the required frequency, and its amplitude varies from the required minimum to the desired maximum.


It is interesting! In 1980, American scientists proved that the human body is surrounded by a magnetic field. Each organ has its own magnetic shell. That is why magnetic field treatment does not cause side effects and addiction. In the process of constantly changing the amplitude and direction of the magnetic induction vector, a high level of biotropy of the magnetic field is provided. If you use a low-frequency effect, it will have magnetobiological effects. Their mechanisms are in no way associated with thermal or electrochemical action.


As medical practice shows, the effect of magnetic fields increases the nonspecific resistance of the body. In addition, VMF contributes to the normalization of homeostasis, and is also accompanied by immunomodulatory, anti-inflammatory, analgesic, hypotensive, and other therapeutic directions.


Experts today estimate at 80-90% the effectiveness of the influence of the magnetic field on the human body. As a result, the fact was revealed that VMF has an inhibitory effect on the development of some transplanted tumors - magnetotherapy in oncology.


These include:

· Mammary cancer.

· Melanoma

· Carcinoma.

· Alveolar cancer of the liver.

· Lymphosarcoma.

· Lungs' cancer.


The following oncological diseases were the least sensitive to this method: leukemia, hemocytoblastosis. According to the results of the study, the following conclusions were made regarding the vortex magnetic field:


The magnetic field has an antitumor effect for the cells of the body, and also has an inhibitory effect on transplanted experimental tumors (up to 90 percent).


The sensitivity to the magnetic field of tumors is quite different: the highest quality result was noted for two types of solid tumors. As for ascites tumors, they are not very sensitive to VMF.

The magnetic field affects the metastatic process. In this case, the level of lymphogenous metastasis of breast cancer is reduced. In addition, as a result of treatment, there is a simultaneous inhibition of the initial tumor by about 28-30 percent.


As for morphological studies in this area, the effect of a magnetic field has a damaging effect on tumor tissue. As a result, it was revealed that under the influence of VMF, extensive areas of necrosis appeared in the fields of tumor cells, hyperemia of small capillary vessels with ruptured vascular walls was detected.


In addition, the magnetic field has a radioprotective effect, which reduces the severity of radiation damage to the body. As a result, the effect of radiation reactions on normal tissues in the body is reduced.


Most importantly, no side effects were found in the treatment of tumors. Research in the field of the effect of a magnetic field on oncological reactions allows us to evaluate the full range of possibilities of VMF, and many methods are being developed to introduce this method of treatment in oncology clinics.


According to the studies, it was revealed that the magnetic field has an insignificant direct effect. It manifests itself in inhibiting the synthesis of tumor cell DNA. In addition, magnetotherapy in oncology affects the cytokinetics of the cell cycle. This is expressed in a small accumulation of cells in the presynthetic phase, which helps to reduce tumor cells in the synthesis phase.


A magnetic field affects all types of immunocompetent cells, while changing their number and activity process. It turns out that the magnetic field is immunomodulatory in nature.

UMP also affects the level of serum activity that occurs in the body. Under her control is the process of immunocompetent peripheral blood cells.


Scientists have proved that the general effect of a magnetic field on the body can enhance the antitumor mechanisms in the body, and treatment in this way can be combined in the treatment of cancer patients with radiation and chemotherapy.


Good to know! System-wide magnetotherapy was first performed to treat breast tumors. This process took place under the supervision of Legiate. In addition, it was found that using a magnetic field to treat postoperative lymphorrhea in patients operated on for breast cancer is an effective and efficient method.


System-wide magnetotherapy can improve the effectiveness of treatment on the primary node, and especially on regional metastases. When this method was used in the postoperative period, the terms and volumes of lymphorrhea were significantly reduced.

It was found that the use of system-wide magnetotherapy in the treatment of cancer patients significantly reduced the intake of narcotic and non-narcotic analgesics. In addition, this method facilitates the tolerance of radiation and polychemotherapy, while significantly increasing their effectiveness.



Magnetic field properties


If we generalize all the properties of the magnetic field in the treatment of oncology, we can draw the following conclusions:


As a result, the influence of system-wide magnetotherapy has significantly reduced the severity of radiation reactions during chemotherapy. In addition, there was a decrease in the severity of the general toxic syndrome.


The magnetic field contributes to the rapid resorption of the tumor, and also increases the level of effectiveness of chemoradiation effects on the human body.


Reduces the risk of postoperative complications. In addition, the terms of postoperative lymphorrhea are significantly reduced.


When applying magnetic field treatment, a tendency toward normalization of cellular and humoral immunity indicators was revealed.


If we compare the general literature data, in the treatment of UMP over the past five years, the survival rate of patients with this diagnosis has significantly increased.


The magnetic field allows patients to tolerate treatment well even with a positive symptomatic effect. In addition, the ability of magnetotherapy to actively influence the course of concomitant diseases was noted. Among them, relief of pain syndromes, a decrease in local and inflammatory reactions, a positive effect on the psychological state of the patient, as well as on his general condition, were revealed.


As for the prospects for the development of system-wide magnetotherapy in oncology, it is not limited to treating only the mammary gland. Over time, clinical studies have been conducted that allow you to treat oncological diseases of various locations with a magnetic field.


Today, system-wide magnetotherapy is used to treat cancer patients, both in the initial stage and in severe. This treatment method does not cause side effects, while helping patients recover quickly enough after a disease.


If you treat cancer with the help of system-wide magnetotherapy, you should know that effective informative channels are being developed to provide feedback on-line monitoring of the state of the body during the procedure.


It turns out that the treatment of cancer with the help of magnetotherapy is a breakthrough in medicine, facilitating the fate of the patient.



The use of magnetic fields in an oncology clinic


The clinical use of MP in oncology has long remained unclaimed. However, despite the lack of a satisfactory theoretical justification of the mechanisms of antitumor action of MPs and the lack of appropriate guidelines for their use, magnetotherapy of malignant neoplasms is gradually moving from the field of experimental research to the clinic. This is evidenced by periodically appearing messages from various medical institutions.


First of all, magnetotherapy has become widespread in the oncology clinic as a method of additional physiotherapeutic treatment in the pre- and postoperative period to restore and eliminate the effects of radical antitumor treatment [14].


It is known that a tumor is a powerful desynchronizer of biological processes. Already from the very beginning of the development of the tumor, there is a violation of the coordination of metabolic processes, neuroendocrine regulation, increased energy costs, tension of the body's defenses and exhaustion, the prevalence of stress, etc. The consequences of chemoradiotherapy and surgical treatment are often manifested by changes in the hypothalamic-pituitary and adrenal systems, which leads to endocrine, autonomic-vascular and neuropsychic disorders, as well as impaired lymph and blood circulation, hypercoagulation, immunosuppression theta.


Neurophysiological studies of Yu.A. Kholodov [49] gives reason to believe that the effect of MP in the treatment of cancer patients is expressed in the development of reactions that favorably affect sleep, emotional state, mental stress, pain and the general condition of the patient.


Research A.M. Demetsky et al. [17] the influence of MP on the pathogenesis of the wound process after radical surgery showed that the effect of MP contributed to the acceleration of wound healing in the absence of ulcers, necrosis, inflammatory foci and tissue infiltration, as well as coarse scars that compress the vascular and nerve bundles. The action of MP helped to improve transcapillary metabolism, increase blood flow and supply oxygen to the tissues, slow down the sclerosis process, form new ones and open previous lymphatic collaterals, which stimulates lymphatic drainage and has a positive effect on such postoperative complications as lymphatic edema, lymphorrhea, venous outflow disorders, phlebitis. and thrombophlebitis.


The data presented show the justification for the use of magnetotherapy in the rehabilitation treatment of cancer patients to relieve the severity of pain, improve the general condition of patients, accelerate reparative processes, normalize blood system parameters, and eliminate postoperative complications. The value of these methods is that magnetotherapy has no direct contraindications in cancer patients.


The direct antitumor effect of MP in the treatment of cancer patients in our country began to be used, starting in the 70s.


A.K. Pankov et al. [38], in combination with radiation therapy in the treatment of skin cancer, lower lip cancer and other localizations, applied the effect of the Polyus apparatus. Analysis of long-term treatment results showed a slight decrease in disease recurrence.


In [45], regression of breast tumors in the preoperative period was observed with direct exposure to the tumor with a ring magnet for 4 hours daily for 10-14 days. A decrease in the size of the neoplasm was observed already two to three days after the start of treatment. The overall tumor regression rate was 60.5%. After surgery, the removed breast tumors were subjected to morphological examination. The characteristic changes were foci of necrosis and hemorrhage, dystrophic and necrobiotic changes in tumor cells with their replacement by stroma elements and adipose tissue. No complete regression of tumors was observed even when exposed to MP for 22 days. To increase the effectiveness of treatment, the authors consider it necessary to select the type of magnet and modes of exposure.


G.A. Krumina et al. [24] used MP to increase the tolerability of chemotherapy in cancer patients. It was supposed to compensate for toxic lesions that cause inhibition of hematopoiesis and impaired neuropsychic state of the patient (depression, impaired sleep, appetite, increased emotional lability). The treatment of 71 patients with malignant glial tumors of the brain was observed. Patients received vinblastine, fluorofur, methotrexate, cyclophosphamide when exposed to variable MP. Inhibition of hematopoiesis was determined by the number of leukocytes and the value of the mononuclear index of blood. Inhibition of hematopoiesis in the group of (control) patients without magnetotherapy was 71%, while in the group of (main) treated with MP, it was 63%. The need for blood transfusions was in 75% of cases in the control group and only 14% in the main group, which allowed reducing the number of necessary blood transfusions by more than 5 times. The psycho-depressive syndrome observed in all patients in the control group developed in only 30% of patients exposed to MP. Moreover, in all these patients it was not very pronounced and was not accompanied by changes in the EEG. In 70% of patients after magnetotherapy, there was an improvement in sleep, mood and appetite.


The effect of an invitro-variable MP on immunocompetent blood cells and the colony-forming ability of bone marrow cells was studied by S.S. Besselites et al. [9]. The experiments were carried out on blood samples of hematological patients with various diseases of the blood system using the Magniter AMT-01 apparatus (30 mT, exposure time 30 min). The effect of MP on blood cells and bone marrow did not adversely affect their immunological and growth characteristics. On the contrary, the phagocytic activity of leukocytes increased, positive dynamics of the content of T-lymphocytes was observed. With an increase in exposure duration, the initially high rates of the colony-forming ability of bone marrow cells in acute leukemia decreased. Of interest in this regard are data on an increase in the phagocytic activity of peripheral blood leukocytes of oncological and other patients under the influence of a weak variable MP.


In recent years, increasingly began to appear reports about the successful use of vortex magnetic fields (VMF) in the treatment of cancer patients.


The first data on the use of VMF in antitumor treatment of patients relate to the works performed by N.G. Bakhmutsky et al. [6,8]. In the treatment process of cancer patients, the Magnitoturbotron installation was used. The applied method of magnetotherapy was a simultaneous and synchronous effect on all organs and systems of the patient with a rotating, smoothly modulated in amplitude VMF.


To assess the antitumor efficacy of this effect, clinical studies of the body's reactions to the general effect of the high-frequency treatment of the Magnitoturbotron installation for a group of patients (51 people) with a confirmed diagnosis of generalized form of stage IV breast cancer were performed. Treatment of patients with a primary tumor not removed did not begin earlier than 2 months after the end of a course of chemoradiotherapy. A study of the dynamics of tumor growth showed that in 27 patients the size of tumor formations decreased during the 30-day course of treatment by more than 50%. Simultaneously with the decrease in the size of the tumors, a decrease in their density and an increase in the mobility were noted. However, after 1 - 1.5 months, the picture of the tumor process was restored. The symptomatic effect of treatment in all patients was evaluated positively.


The second group included 54 patients with a diagnosis of stage II – IIa breast cancer. The treatment was carried out according to the following scheme: 30 preoperative VMF procedures + surgery + 30 postoperative VMF procedures. In 47 patients, a decrease in the size and density of tumors during preoperative treatment from 35% to 90% was recorded. Morphological studies of the surgical material indicated the presence of signs of therapeutic pathomorphism in the tumors.


In the works of V.P. Letyagina et al. [26,27,61] studied the use of VMF exposure in pre- and postoperative treatment of patients with breast cancer. Studies have shown that the use of magnetotherapy in the scheme of preoperative chemoradiation treatment for a group of patients (114 people) with locally advanced stage III breast cancer improved the immediate results of therapy in relation to the standard course of treatment. This was manifested primarily in achieving greater efficacy of impact on regional metastases of 87% (without UHF exposure of 52.3%), as well as in registering pronounced therapeutic pathomorphosis (grade 3-4) in tumor tissue in 55.5% of cases (without UHF therapy - 47%). The use of VMF for the treatment of postoperative lymphorrhea after radical surgery for stage I – III breast cancer was investigated. For a group of patients (35 people) showed that in most patients when exposed to VMF, lymphorrhea decreased from 250 ... 300 ml per day to 50 ml or completely stopped, which helped to reduce the length of hospital stay.


Of interest are studies of the immunomodulatory effect of VMF. THEM. Miroshnichenko et al. [31] determined the dynamic changes in the number of certain populations of immunocompetent cells (ICC) and their functions during the course of magnetotherapy of cancer patients undergoing treatment at the installation; Magnitoturbotron ;. Studies have shown that in all patients, under the influence of VMF-exposure, there were changes in both the number and functions for all types of ICC. In this case, the action of VMF was immunomodulatory in nature. The authors suggest that the studied mechanism of action of HMF on the ICC is realized through their updating due to the migration of bone marrow precursors. It is also assumed that the effect of VMF can be determined by normalizing the TCA level, which controls the process of updating the peripheral blood ICC due to the influx of cells from the bone marrow and differentiation of T-series cells.


T.G. Milevskaya et al. [30] compared baseline immunity with data obtained after preoperative treatment of cancer patients with and without UHF exposure. It is noted that in the group of patients treated with magnetic and radiation therapy, there was a tendency to increase the percentage of total and active T-lymphocytes, as well as to normalize the value of the index of the ratio of helpers to suppressors (Tx / Ts) in comparison with changes in the corresponding parameters in the group of patients who received only radiation therapy (T-total: 59.5% - 62.1% and 57.8% - 56.9%; T-active: 32.7% - 34.1% and 32.8 % - 32.9%; Тx / Тs-index: 2.3 - 3.03 and 2.73 - 2.42, respectively). The above results allowed the authors to suggest the presence of an immunomodulatory effect of exposure to VMF, the orientation and results of which depend on the initial state of patients.


Assertions of a similar kind are made in [50]. Studying the state of the immune system of patients with stage 2–3 breast cancer during complex treatment using magnetotherapy at the Magnitoturbotron installation showed that the action of VMF leads to the activation of the T-cell component of the immune system and helps to reduce the damaging effect of radiation on ICC. The ratio of the helper-suppressor fraction of lymphocytes in favor of helpers changed, which is a positive moment before surgery in the course of systemic therapy.


The reaction of the individual components of cellular and humoral immunity were investigated by Y. A. Rodin et al [41]. It is shown that the result of VMF-therapy of oncological patients, there is a stable trend normalize the levels of immunoglobulin, the reduction in the level of circulating immunological complexes (CIC), a significant increase in T-helper activity (mostly at the expense of T-active lymphocytes), increased levels of the phagocytic index and the degree of completion of phagocytosis. On this basis, the authors conclude that the total PMF-exposure causes irritation of the bone marrow and increase the proliferative processes. This confirms the feasibility of combining the effects of the PMF in the treatment of cancer patients and the traditional methods of radiation and chemotherapy, enhance the immunosuppression of cancer patients.


Examples with different degree of confidence illustrate the application of various types of MP in Oncology. In each of the cases, the parameters and modes of exposure to MP, and the object and scheme of treatment was chosen, usually randomly. Analysis of literature data shows that of particular interest is the method the overall impact of the PMF is characterized by a high level of biotapestry. Different authors differently evaluate the effectiveness of the use of VMF in the treatment of neoplastic diseases, however, the General conclusion is the absence of any signs of damage to healthy tissue and suppressing the immune and hematopoietic systems, which allows us to recommend the use of PMF exposure in different schemes of pre - and postoperative treatment of cancer patients.


I invite you, including, to get acquainted with the extremely important dissertation of Rostov scientists. Autohemochemotherapy in combination with extracorporeal magnetic blood processing in the complex treatment of malignant bone tumors, Ausheva Tatyana Valerevna.


http://www.dslib.net/onkologia/autogemohimioterapija-v-sochetanii-s-jekstrakorporalnoj-magnitnoj-obrabotkoj-krovi.html


Autohemochemotherapy in combination with extracorporeal magnetic blood processing in the complex treatment of malignant bone tumors.


Malignant bone tumors due to the peculiarities of their growth and clinical course are among the most prognostically unfavorable malignant tumors. According to the literature, the incidence of primary malignant tumors is small and reaches no more than 1-1.5% in the structure of oncological pathology, which is 1-1.2 cases per 100,000 population. In most cases, they occur in young people, i.e. socially significant contingent of the population, and are characterized by aggressiveness of the course and a high tendency to early hematogenous metastasis, mainly to the lungs (up to 90 - 95% of the case in the first two years from the onset of the disease), which is the main cause of death of patients and causes an unsatisfactory prognosis. The five-year survival rate of patients with primary malignant bone tumors is not more than 50-60%.


Until the mid-70s of the XX century, the main method of treating malignant bone tumors was a surgical one, and the operation of choice was, as a rule, crippling intervention - amputation or exarticulation of the limb. But even these grave interventions did not bring the desired results. So, for example, with osteogenic sarcoma, 5-year survival did not exceed 12 - 18%. The use of pre- and postoperative chemotherapy allowed not only to increase the 5-year survival rates to 50-60%, but also the percentage of organ-preserving surgeries to 75-80%, however, even these results cannot be considered as meeting the requirements of modern

oncology. Despite the fact that many works have convincingly shown that the use of chemotherapy in the complex treatment of malignant tumors of bones significantly improves the prognosis of the disease, this section of oncology is all still not enough.


With the development of new drugs, opportunities expand chemotherapy and the number of patients subject to special treatment. However, even new drugs do not always provide the opportunity to obtain the desired results, and their high cost often makes it impossible for all patients to receive treatment. Therefore, the search for new methods is of particular importance.


The introduction of drugs. In recent years, more research dedicated to extracorporeal pharmacotherapy as one of the most promising areas in drug treatment, an alternative traditional methods of drug administration. Extracorporeal pharmacotherapy involves reinfusion of blood cells after incubation with drugs to change the properties of cells or directional transport to target organs.


Examples of in vitro antitumor pharmacotherapy are being developed at Rostov Research oncological institute methods involving the introduction of cytostatics on autologous body tissues after their extracorporeal incubation (autohemochemotherapy, autolymphochemotherapy, autoplasmochemotherapy, autothromboerythroleukotherapy, homolymphochemotherapy, etc.) These methods can increase the effectiveness of antitumor chemotherapy with a simultaneous decrease in its toxic effects and do not have pronounced immunosuppressive action, in contrast to systemic 5 polychemotherapy with standard solvents. In recent years, more and more attention has been paid not only to extracorporeal pharmacotherapy, but also the possibility of its modification various physical factors, in particular the action of a magnetic field.


For example, the treatment of breast cancer convincingly proved that under the influence of a magnetic field the degree of cytostatic binding to erythrocyte membranes increases incubating it with auto blood (30%), which in turn contributes to reduction of toxic side effects of chemotherapy, significantly increases its effectiveness even in comparison with traditional.

Thus, in our opinion, it is advisable to use the well-known method of autohemochemotherapy, modified by extracorporeal magnetic treatment of a mixture of autologous blood with a cytostatic agent, as a neoadjuvant component in the complex treatment of primary malignant bone tumors.


The aim of this study was to improve the immediate and long-term results of the treatment of patients with malignant bone tumors by using autohemochemotherapy in combination with extracorporeal magnetic blood processing.

0 views

© 2018 Magnetic Technologies

UAE, Dubai

 

Office #202, Faisal Al Gurg Bldg.,

Oud Metha, 10th street

+971 4 3966639

 

info@weathergenerator.net

magtech@emirates.net.ae

magneticeast.ae

Help